A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Public ClinicalTrials.gov record NCT06305767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
Study identification
- NCT ID
- NCT06305767
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 230 participants
Conditions and interventions
Conditions
Interventions
- Enfortumab Vedotin Biological
- Intismeran autogene Biological
- Pembrolizumab Biological
- Placebo Other
- Surgery (RC plus PLND) Procedure
Biological · Other · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2024
- Primary completion
- Apr 22, 2027
- Completion
- Oct 19, 2031
- Last update posted
- Jan 12, 2026
2024 – 2031
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104) | Los Angeles | California | 90095 | — |
| AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102) | Orlando | Florida | 32804 | — |
| University of Chicago Medical Center ( Site 0109) | Chicago | Illinois | 60637 | — |
| University of Iowa ( Site 0110) | Iowa City | Iowa | 52242 | — |
| Icahn School of Medicine at Mount Sinai ( Site 0101) | New York | New York | 10029 | — |
| Duke Cancer Institute ( Site 0107) | Durham | North Carolina | 27710 | — |
| Cleveland Clinic Main ( Site 0100) | Cleveland | Ohio | 44195 | — |
| Fox Chase Cancer Center ( Site 0106) | Philadelphia | Pennsylvania | 19111 | — |
| UT Southwestern Medical Center ( Site 0103) | Dallas | Texas | 75390 | — |
| Houston Methodist Hospital-Department of Urology ( Site 0111) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06305767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 12, 2026 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06305767 live on ClinicalTrials.gov.